Overall, these data show that, in contrast to the behavior of CT26/HER2 tumors, 4T1.2/HER2 tumors regress via the induction of HER263–71-specific CD8+ CTL activity in animals and that CD80 is not associated with the regression of this tumor type. This evidence concerns the gene CD80 and neoplasm.